Booster Shot: Novavax vaccine shows 90% efficacy, J&J 66%
Novavax said its NVX-CoV2373 demonstrated a 90% efficacy in phase 3
trials in the UK, taking it closer to approval by the UK health
authorities. J&J's single-dose vaccine showed an overall efficacy of
66% and 85% efficacy in preventing death (severe disease) across all
age and ethnic groups.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/booster-shot-novavax-vaccine-shows-90-efficacy-jj-66/articleshow/80594672.cms
trials in the UK, taking it closer to approval by the UK health
authorities. J&J's single-dose vaccine showed an overall efficacy of
66% and 85% efficacy in preventing death (severe disease) across all
age and ethnic groups.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/booster-shot-novavax-vaccine-shows-90-efficacy-jj-66/articleshow/80594672.cms
Comments
Post a Comment